Treatment of familial hypercholesterolemia: Is there a need beyond Statin therapy?

Current Atherosclerosis Reports

Volumn 14, Issue 1, 2012, Pages 11-16

  Raper, Anna ^a   Kolansky, Daniel M ^a   Cuchel, Marina ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Familial hypercholesterolemia; Lipid lowering drugs

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; APOLIPOPROTEIN B ANTISENSE OLIGONUCLEOTIDE; BILE ACID SEQUESTRANT; CSL 111; EPROTIROME; EZETIMIBE; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOMITAPIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN INHIBITOR; MIPOMERSEN; NICOTINIC ACID; REGN 727; SAR 236553; THYROID HORMONE DERIVATIVE; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; APHERESIS; ARTICLE; ATHEROSCLEROSIS; BONE DISEASE; CARDIOVASCULAR RISK; CATABOLISM; CHOLESTEROL BLOOD LEVEL; DIET THERAPY; DISEASE SEVERITY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; EXERCISE; FAMILIAL HYPERCHOLESTEROLEMIA; FATTY LIVER; FLU LIKE SYNDROME; GENE REPLACEMENT THERAPY; HEART DISEASE; HETEROZYGOSITY; HIGH RISK PATIENT; HOMOZYGOSITY; HUMAN; INJECTION SITE REACTION; LIFESTYLE MODIFICATION; LIOTHYRONINE BLOOD LEVEL; LIPID STORAGE; MONOTHERAPY; MYALGIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PERIPHERAL VASCULAR DISEASE; PRESCRIPTION; SIDE EFFECT; THYROTROPIN BLOOD LEVEL;

CHOLESTEROL, LDL; GENE THERAPY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPOPROTEINEMIA TYPE II; TREATMENT OUTCOME;

EID: 84857639583     PISSN: 15233804     EISSN: 15346242     Source Type: Journal    
DOI: 10.1007/s11883-011-0215-y     Document Type: Article

References (53)

1. PN Hopkins PP Toth CM Ballantyne DJ Rader 2011 Familial Hypercholesterolemias: prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia J Clin Lipidol 5 3 S9 S17 21600530 10.1016/j.jacl.2011.03. 452
2. Goldstein JL, Hobbs HH, Brown MS. Familial hypercholesterolemia. In: The metabolic and molecular bases of inherited disease. New York: McGraw-Hil; 2001. pp. 2863-913.
3. D Marks M Thorogood HAW Neil SE Humphries 2003 A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia Atherosclerosis 168 1 1 14 12732381 10.1016/S0021-9150(02)00330-1 1:CAS:528:DC%2BD3sXjsVertbg%3D (Pubitemid 36559596)
4. DM Kolansky M Cuchel BJ Clark, et al. 2008 Longitudinal evaluation and assessment of cardiovascular disease in patients with homozygous familial hypercholesterolemia Am J Cardiol 102 11 1438 1443 19026292 10.1016/j.amjcard. 2008.07.035
5. MA Austin CM Hutter RL Zimmern SE Humphries 2004 Familial hypercholesterolemia and coronary heart disease: a HuGE association review Am J Epidemiol 160 5 421 429 15321838 10.1093/aje/kwh237 (Pubitemid 39166974)
6. GF Watts B Lewis DR Sullivan 2007 Familial hypercholesterolemia: a missed opportunity in preventive medicine Nat Clin Pract Cardiovasc Med 4 8 404 405 17593912 10.1038/ncpcardio0941 (Pubitemid 47180321)
7. JI Cleeman SM Grundy D Becker, et al. 2001 Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) JAMA-J Am Med Assoc 285 19 2486 2497 10.1001/jama.285.19. 2486 (Pubitemid 32433843)
8. SM Grundy JI Cleeman CNB Merz, et al. 2004 Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines Circulation 110 2 227 239 15249516 10.1161/01.CIR. 0000133317.49796.0E (Pubitemid 38924592)
9. I Graham D Atar K Borch-Johnsen, et al. 2007 European guidelines on cardiovascular disease prevention in clinical practice: executive summary Eur Hear J 28 19 2375 2414 10.1093/eurheartj/ehm316 (Pubitemid 47542237)
10. Versmissen J, Oosterveer DM, Yazdanpanah M, et al. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. Br Med J. 2008;337:bmj.a2423.
11. J Rodenburg MN Vissers A Wiegman, et al. 2007 Statin treatment in children with familial hypercholesterolemia-the younger, the better Circulation 116 6 664 668 17664376 10.1161/CIRCULATIONAHA.106.671016 1:CAS:528: DC%2BD2sXotlahtrs%3D (Pubitemid 47356351)
12. EA Stein 2009 Other therapies for reducing low-density lipoprotein cholesterol: medications in development Endocrinol Metabol Clin North Am 38 1 99 119 10.1016/j.ecl.2008.11.011 1:CAS:528:DC%2BD1MXkt1eks74%3D
13. AH Pijlman R Huijgen SN Verhagen, et al. 2010 Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands Atherosclerosis 209 1 189 194 19818960 10.1016/j.atherosclerosis.2009.09.014 1:CAS:528:DC%2BC3cXis1egu7o%3D This work shows that only 21% of an FH population reached their target LDL level, determined by European and Dutch guidelines. The study showed that there needs to be better utilization of currently available treatments as well as new options for FH patients. More studies such as this in the United States would be valuable in quantifying how great the treatment need is for FH patients
14. DJ Rader J Cohen HH Hobbs 2003 Monogenic hypercholesterolemia: new insights in pathogenesis and treatment J Clin Investig 111 12 1795 1803 12813012 1:CAS:528:DC%2BD3sXkvV2ktbw%3D (Pubitemid 38057721)
15. C Enger R Gately EE Ming SJ Niemcryk L Williams AT McAfee 2010 Pharmacoepidemiology safety study of fibrate and statin concomitant therapy Am J Cardiol 106 11 1594 1601 21094360 10.1016/j.amjcard.2010.07.041 1:CAS:528:DC%2BC3cXhsVGit7fK
16. NIH stops clinical trial on combination cholesterol treatment. In: press release. National Institutes of Health; 5/26/2011.
17. JJP Kastelein ML Bots 2009 Statin therapy with ezetimibe or niacin in high-risk patients N Engl J Med 361 22 2180 2183 19915218 10.1056/NEJMe0908841 1:CAS:528:DC%2BD1MXhsFWgs7rI
18. SP Kennedy GP Barnas MJ Schmidt MS Glisczinski AC Paniagua 2011 Efficacy and tolerability of once-weekly rosuvastatin in patients with previous statin intolerance J Clin Lipidol 5 4 308 315 21784377 10.1016/j.jacl.2011.03.454
19. BS Sachais J Katz J Ross DJ Rader 2005 Long-term effects of LDL apheresis in patients with severe hypercholesterolemia J Clin Apher 20 4 252 255 15880364 10.1002/jca.20036
20. H Mabuchi J Koizumi M Shimizu, et al. 1998 Long-term efficacy of low density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia Am J Cardiol 82 12 1489 1495 9874053 10.1016/S0002-9149(98) 00692-4 1:STN:280:DyaK1M%2FovFCnuw%3D%3D (Pubitemid 29006472)
21. GR Thompson 2003 LDL apheresis Atherosclerosis 167 1 1 13 12618263 10.1016/S0021-9150(02)00251-4 1:CAS:528:DC%2BD3sXhs1CmsLw%3D (Pubitemid 36258395)
22. F Kakaei S Nikeghbalian K Kazemi, et al. 2009 Liver transplantation for homozygous familial hypercholesterolemia: two case reports Transplant Proc 41 7 2939 2941 19765481 10.1016/j.transproceed.2009.07.028 1:STN:280: DC%2BD1MnjsFCrsA%3D%3D
23. CP Cannon S Shah HM Dansky, et al. 2010 Safety of anacetrapib in patients with or at high risk for coronary heart disease N Engl J Med 363 25 2406 2415 21082868 10.1056/NEJMoa1009744 1:CAS:528:DC%2BC3cXhsF2ltLfL This work describes a study of anacetrapib, a CETP inhibitor that raised HDL and reduced LDL with an acceptable adverse event profile
24. MH Davidson 2010 Update on CETP inhibition J Clin Lipidol 4 5 394 398 21122682 10.1016/j.jacl.2010.08.003
25. DA Blasiole RA Davis AD Attie 2007 The physiological and molecular regulation of lipoprotein assembly and secretion Mol Biosyst 3 9 608 619 17700861 10.1039/b700706j 1:CAS:528:DC%2BD2sXptVWiurc%3D (Pubitemid 47258227)
26. JR Wetterau RE Gregg TW Harrity, et al. 1998 An MTP inhibitor that normalizes atherogenic lipoprotein levels in WHHL rabbits Science 282 5389 751 754 9784135 10.1126/science.282.5389.751 1:CAS:528:DyaK1cXmvFyjsb8%3D (Pubitemid 28489389)
27. M Cuchel LT Bloedon PO Szapary, et al. 2007 Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia N Engl J Med 356 2 148 156 17215532 10.1056/NEJMoa061189 1:CAS:528:DC%2BD2sXksVKmtQ%3D%3D (Pubitemid 46089675)
28. Aegerion Pharmaceuticals Announces Phase III 56-Week Data in HoFH Patients Taking Investigational Lomitapide is Consistent With 26-Week Data. In: Press release. Aegerion Pharmaceuticals; 5/31/2011.
29. RM Crooke MJ Graham KM Lemonidis CP Whipple S Koo RJ Perera 2005 An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis J Lipid Res 46 5 872 884 15716585 10.1194/jlr.M400492-JLR200 1:CAS:528:DC%2BD2MXktFaqtb4%3D
30. AE Mullick WX Fu MJ Graham, et al. 2011 Antisense oligonucleotide reduction of apoB-ameliorated atherosclerosis in LDL receptor-deficient mice J Lipid Res 52 5 885 896 21343632 10.1194/jlr.M011791 1:CAS:528: DC%2BC3MXltFGhtLo%3D
31. I Gouni-Berthold HK Berthold 2011 Antisense oligonucleotides for the treatment of dyslipidemia Curr Pharm Des 17 9 950 960 21418033 10.2174/138161211795428830 1:CAS:528:DC%2BC3MXlvFyktL8%3D
32. F Akdim ME Visser DL Tribble, et al. 2010 Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia Am J Cardiol 105 10 1413 1419 20451687 10.1016/j.amjcard.2010.01.003 1:CAS:528:DC%2BC3cXlslyksbg%3D
33. Stein EA, Dufour R, Gagne C, et al. A randomized, double-blind, placebo-controlled study to assess efficacy and safety of mipomersen as add-on therapy in heterozygous familial hypercholesterolemia patients with coronary artery disease. Eur Hear J. 2010;31:898 (Abstract).
34. FJ Raal RD Santos DJ Blom, et al. 2010 Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial Lancet 375 9719 998 1006 20227758 10.1016/S0140- 6736(10)60284-X 1:CAS:528:DC%2BC3cXjs1ait74%3D
35. M Abifadel M Varret JP Rabes, et al. 2003 Mutations in PCSK9 cause autosomal dominant hypercholesterolemia Nat Genet 34 2 154 156 12730697 10.1038/ng1161 1:CAS:528:DC%2BD3sXktFSlt70%3D (Pubitemid 36666925)
36. AK Soutar RP Naoumova 2007 Mechanisms of disease: genetic causes of familial hypercholesterolemia Nat Clin Pract Cardiovasc Med 4 4 214 225 17380167 10.1038/ncpcardio0836 1:CAS:528:DC%2BD2sXjsVCjtbw%3D (Pubitemid 46502094)
37. JC Cohen E Boerwinkle TH Mosley HH Hobbs 2006 Sequence variations in PCSK9, low LDL, and protection against coronary heart disease N Engl J Med 354 12 1264 1272 16554528 10.1056/NEJMoa054013 1:CAS:528:DC%2BD28Xislequr8%3D
38. CJ Duff NM Hooper 2011 PCSK9: an emerging target for treatment of hypercholesterolemia Expert Opin Ther Targets 15 2 157 168 21204732 10.1517/14728222.2011.547480 1:CAS:528:DC%2BC3MXktVehtQ%3D%3D
39. Swergold G, Biedermann S, Renard R, et al. REGN727/SAR236553, A fully human proprotein convertase subtilisin kexin 9 (PCSK9) monoclonal antibody: effects on safety and lipid and lipoprotein profiles when administered subcutaneously. J Am Coll Cardiol. 2011;57(14):E2023 (Abstract).
40. ND Danese PW Ladenson CL Meinert NR Powe 2000 Effect of thyroxine therapy on serum lipoproteins in patients with mild thyroid failure: a quantitative review of the literature J Clin Endocrinol Metab 85 9 2993 3001 10999775 10.1210/jc.85.9.2993 1:CAS:528:DC%2BD3cXmsVKrtbo%3D
41. GR Thompson AK Soutar FA Spengel A Jadhav SJP Gavigan NB Myant 1981 Defects of receptor-mediated low-density lipoprotein catabolism in homozygous familial hypercholesterolemia and hypothyroidism in vivo Proc Natl Acad Sci USA-Biol Sci 78 4 2591 2595 10.1073/pnas.78.4.2591 1:CAS:528:DyaL3MXitVKltL0%3D (Pubitemid 11067253)
42. GC Ness LC Pendleton YC Li JYL Chiang 1990 Effect of thyroid hormone on hepatic cholesterol 7-alpha hydroxylase, LDL receptor, HMG-CoA reductase, farnesyl pyrophosphate synthetase and apolipoprotein A-I mRNA levels in hypophysectomized rats Biochem Biophys Res Commun 172 3 1150 1156 2123100 10.1016/0006-291X(90)91568-D 1:CAS:528:DyaK3MXpsFU%3D
43. JD Baxter WH Dillmann BL West, et al. 2001 Selective modulation of thyroid hormone receptor action J Steroid Biochem Mol Biol 76 1-5 31 42 11384861 10.1016/S0960-0760(01)00052-8 1:CAS:528:DC%2BD3MXks1alsbg%3D (Pubitemid 32510665)
44. PW Ladenson JD Kristensen EC Ridgway, et al. 2010 Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia N Engl J Med 362 10 906 916 20220185 10.1056/NEJMoa0905633 1:CAS:528:DC%2BC3cXjt1ylsL8%3D
45. SE Nissen T Tsunoda EM Tuzcu, et al. 2003 Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes-a randomized controlled trial JAMA-J Am Med Assoc 290 17 2292 2300 10.1001/jama.290.17.2292 1:CAS:528:DC%2BD3sXovVCjtbc%3D (Pubitemid 37430562)
46. JA Shaw A Bobik A Murphy, et al. 2008 Infusion of reconstituted high-density lipoprotein leads to acute changes in human atherosclerotic plaque Circ Res 103 10 1084 1091 18832751 10.1161/CIRCRESAHA.108.182063 1:CAS:528:DC%2BD1cXhtlaqs7fO
47. JC Tardif J Gregoire PL L'Allier, et al. 2007 Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis-a randomized controlled trial JAMA-J Am Med Assoc 297 15 1675 1682 10.1001/jama.297.15. jpc70004 (Pubitemid 46631626)
48. MN Nanjee JE Doran PG Lerch NE Miller 1999 Acute effects of intravenous infusion of apoA1/phosphatidylcholine discs on plasma lipoproteins in humans Arterioscler Thromb Vasc Biol 19 4 979 989 10195926 10.1161/01.ATV.19.4.979 1:CAS:528:DyaK1MXislaru7o%3D (Pubitemid 29177346)
49. MN Nanjee CJ Cooke R Garvin, et al. 2001 Intravenous apoA-I/lecithin discs increase pre-beta-HDL concentration in tissue fluid and stimulate reverse cholesterol transport in humans J Lipid Res 42 10 1586 1593 11590214 1:CAS:528:DC%2BD3MXotFGqu7o%3D (Pubitemid 33020090)
50. M Eriksson LA Carlson TA Miettinen B Angelin 1999 Stimulation of fecal steroid excretion after infusion of recombinant proapolipoprotein A-I-potential reverse cholesterol transport in humans Circulation 100 6 594 598 10441095 1:CAS:528:DyaK1MXlslyjsLo%3D (Pubitemid 29379747)
51. S Patel BG Drew S Nakhla, et al. 2009 Reconstituted high-density lipoprotein increases plasma high-density lipoprotein anti-inflammatory properties and cholesterol efflux capacity in patients with type 2 diabetes J Am Coll Cardiol 53 11 962 971 19281927 10.1016/j.jacc.2008.12.008 1:CAS:528:DC%2BD1MXjtFOjsLg%3D
52. M Grossman DJ Rader DWM Muller, et al. 1995 A pilot-study of ex vivo gene therapy for homozygous familial hypercholesterolaemia Nat Med 1 11 1148 1154 7584986 10.1038/nm1195-1148 1:CAS:528:DyaK2MXptFahs7o%3D
53. SH Kassim JM Wilson DJ Rader 2010 Gene therapy for dyslipidemia: a review of gene replacement and gene inhibition strategies Clin Lipidol 5 6 793 809 10.2217/clp.10.73 1:CAS:528:DC%2BC3cXhsFGlt7bI